Super-Pharm Accused of Systematically Overcharging for Basic Products
Translated & summarized from Now 14 by baba
An Israeli consumer report by C14 alleges that Super-Pharm systematically overcharges for basic hygiene and cleaning products by tens to hundreds of percent compared to competitors. The investigation detailed price differences for five common items, including diapers, baby soap, and formula, highlighting significant markups at Super-Pharm.
The story in 5 lines · by baba
- Super-Pharm allegedly overcharges for basic products.
- Price differences range from tens to hundreds of percent.
- Five specific products were highlighted in the price comparison.
- Consumers face higher costs without price comparisons.
- Super-Pharm declined to comment on the report.
A consumer investigation by C14 has revealed that the Israeli pharmacy chain Super-Pharm significantly overprices basic hygiene and cleaning products compared to other pharmacies and major food retailers. The report highlights that consumers pay substantially more for everyday items at Super-Pharm, suggesting a systematic overcharging practice rather than isolated incidents.
The investigation compared prices for five specific products across different retailers. For instance, Dr. Similarly, Huggies Extra Care diapers were priced at 64.90 shekels at Super-Pharm, versus 44.90 shekels at Bi-Pharm.
Further examples include Johnson's Baby shampoo (750ml), which costs 30.90 shekels at Super-Pharm and 21.90 shekels at Bi-Pharm. Similac Gold Plus Stage 3 infant formula (700g) was priced at 58.90 shekels at Super-Pharm compared to 54.90 shekels at Gabi-Pharm. Finally, Johnson's Baby talcum powder (200g) was sold for 24.90 shekels at Super-Pharm, while available for 17.90 shekels at Bi-Pharm.
C14 stated that these price discrepancies demonstrate a significant financial disadvantage for Israeli consumers already grappling with the high cost of living. The report implies that purchasing from Super-Pharm without prior price comparison results in a costly transaction. Super-Pharm declined to comment on the findings.